Key Drivers
- Margin Compression
- Cash Flow Weakness
- Rich Valuation
AIAI Summary
WAT now looks less like a straightforward high-quality compounder and more like a show-me story: demand is intact and guidance is up, but the BD Life Sciences deal, added debt, and sharply weaker margins/free cash flow mean the stock's rich valuation now depends on fast, proven integration and margin recovery.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Compression
- •Cash Flow Weakness
- •Rich Valuation
WAT still has a strong long-term profitability and cash-generating track record, but the latest quarter showed sharp margin compression, negative free cash flow, and a rich valuation that leaves little margin of safety.
Price Behavior
Key Price Behavior Insights:
- •Lower closes
- •Support test
- •Rally cooled
WAT's rally stalled after a last-month high near $355, with lower closes now signaling weakening momentum and downside risk toward $329–$333, then $309–$301 if support fails.
Sequence of lower closes after the last-month high near $355 signals short-term momentum loss
Sentiment & News
Key News Insights:
- •Q1 Outperformance
- •Raised Outlook
- •FX Sensitivity
Waters delivered a strong Q1 beat and raised guidance on broad-based growth and acquisition-driven gains, but international revenue and currency remain key watchpoints.
The results are positive for Waters' near-term outlook, reinforcing momentum from core demand and acquisitions while keeping foreign-exchange and overseas sales trends in focus
Similar Companies in Healthcare
Other companies in the same sector with AI ratings